Printer Friendly

Switzerland : Novartis' Cosentyx is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients.

Novartis, a global leader in Immunology & Dermatology, announced today first-of-its-kind long-term data showing that Cosentyx (secukinumab) provided sustained improvements in nail and palmoplantar psoriasis out to 2.5 years. These data are unique as it is the first time any biologic has demonstrated long-term efficacy and safety in nail and palmoplantar psoriasis. These new data from a clinical study were presented at the 8th International Congress of Psoriasis from Gene to Clinic in London, UK.

Up to 90% of psoriasis patients may develop nail psoriasis or palmoplantar psoriasis, which affects the palms of the hands and soles of the feet. Both nail and palmoplantar psoriasis heavily impact patients' quality of life leading to reduced mobility, functional impairment and physical discomfort.

Cosentyx addresses the cornerstone cytokine interleukin-17A (IL-17A) involved in the development and progression of psoriasis, and is the first and only fully human IL-17A inhibitor to show sustained skin clearance rates at 5 years in psoriasis. By working to specifically target and inhibit IL-17A, Cosentyx can more effectively address the underlying cause of the disease. To date, psoriasis treatments targeting other, less direct, pathways have not shown long-term efficacy out to 2.5 years in these hard-to-treat forms.

"Patients with nail and palmoplantar psoriasis need effective treatment options to address the significant impact these conditions can have on their day-to-day lives," said Eric Hughes, Global Development Unit Head, Immunology & Dermatology. "As an IL-17A inhibitor, Cosentyx provides a highly targeted treatment option that can not only effectively treat the plaques caused by psoriasis, as evident by recently presented 5-year data, but also hard-to-treat forms and associated arthritic conditions."

In GESTURE, 59% and 53% palmoplantar psoriasis patients who received Cosentyx 300 mg and 150 mg respectively achieved clear or almost clear palms and soles at 2.5 years (as measured by Palmoplantar Investigator's Global Assessment (ppIGA) 0/1). In the TRANSFIGURE study, patients with nail psoriasis who were treated with Cosentyx 300 mg and 150 mg showed a substantial NAPSI (Nail Psoriasis Severity Index) improvement from baseline of -73% and -63% respectively. GESTURE, the largest and longest randomized controlled trial to date in palmoplantar psoriasis patients, and TRANSFIGURE, the first large, controlled trial to report long-term results in nail psoriasis, both demonstrated strong sustainability out to 2.5 years, with a favorable and consistent safety profile, including close to zero injection site reactions or associated pain.

The 8th International Congress of Psoriasis from Gene to Clinic is taking place in London from Thursday 30th November to Saturday 2nd December.

[c] 2017 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).

COPYRIGHT 2017 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Geographic Code:4EUUK
Date:Dec 1, 2017
Words:430
Previous Article:United States : Everence Financial Chooses SS&C for Loan Servicing and Reporting.
Next Article:United States : Latest release delivers advanced data visualization and comprehensive, highly customizable performance analytics.
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters